Loading...
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...
Na minha lista:
| Udgivet i: | Iran Biomed J |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Pasteur Institute
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889503/ https://ncbi.nlm.nih.gov/pubmed/28992681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/ibj.22.3.180 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|